Nanotechnology Now

Our NanoNews Digest Sponsors







Heifer International

Wikipedia Affiliate Button


Home > News > Insiders Bullish on BioSante Pharma

January 14th, 2008

Insiders Bullish on BioSante Pharma

Abstract:
Over the next year and beyond, LibiGel is expected to be the key value-driver for BioSante, especially now that the Company has achieved clarity on the requirements for FDA approval and has already started the process with just one more Phase 3 efficacy trial due to commence early this year. Key Phase 3 safety data is expected in the latter half of 2009 with an anticipated NDA filing occurring in the first half of 2010 and market launch about one year later. However, shareholders are likely to realize the value of LibiGel much sooner in the form of a lucrative licensing deal or possibly even a buyout based on the product's tremendous sales potential as the first and only FDA-approved treatment for FSD in the US. Both the CEO (Stephen Simes) and the CFO (Phillip Donenberg) of the Company have a solid track record in creating and building value for shareholders with previous success at Unimed and Gynex before they were acquired by Solvay and Savient Pharma, respectively. Also, the recent insider buying suggests that executives and directors at BioSante feel the stock is currently undervalued and is an encouraging sign for investors who may have been waiting on the sidelines for an entry point.

Source:
seekingalpha.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

How do cold ions slide May 24th, 2013

Heinrich Rohrer dies at 79; a father of nanotechnology: With IBM colleague Gerd Binnig, Rohrer invented the scanning tunneling microscope, which can show individual atoms on a surface and move them around May 23rd, 2013

Gold nanocrystal vibration captured on billion-frames-per-second film May 23rd, 2013

Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home: Glowing Plant seeks funds via crowdfunding and raises almost $400,000 May 23rd, 2013

Investments/IPO's/Splits

Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013

Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013

Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013

Nanometrics Announces Upcoming Investor Events May 14th, 2013

Nanomedicine

UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013

Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013

How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013

MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals

Heinrich Rohrer dies at 79; a father of nanotechnology: With IBM colleague Gerd Binnig, Rohrer invented the scanning tunneling microscope, which can show individual atoms on a surface and move them around May 23rd, 2013

IDTechEx launches online Market Intelligence Portal May 23rd, 2013

Whirlpools on the Nanoscale Could Multiply Magnetic Memory: At the Advanced Light Source, Berkeley Lab scientists join an international team to control spin orientation in magnetic nanodisks May 22nd, 2013

UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project








abbigliamento uomo
Computer Accessories
© Copyright 1999-2013 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE